By Sudeep Basu, Ph.D., Global Practice Leader, Innovation Services, TechVision Group, Frost & Sullivan
Cell therapies constitute one of the most prosperous fields of research, as they advanceing the creation of new companies offering both products and services within a vast range of logical innovations, from autologous cell transplantation in the clinics to cell-printed tissue for research use and validation tests in pharmaceutical development. According to Frost & Sullivan, the cell therapy manufacturing industry is expected to experience a great revolution in terms of products launched and customer niches penetrated in the next five years. Therefore, costs associated with cycle developmental time around novel solutions become decisive for commercialization success. Flexible manufacturing platforms and smart-based quality control systems embracing a broad spectrum of adjacent technology solutions are poised to lead the way toward world-class, high performance, cost-effective cell therapy manufacturing platforms and facilities.
Frost & Sullivan recently invited industry leaders in biopharmaceutical manufacturing to participate in a new and unique thought leadership forum, our Virtual Think Tank series. This forum brought together leading minds in manufacturing to discuss challenges, strategies, techniques, and barriers to new technology implementation in downstream processing.